A multidisciplinary approach to optimizing care of patients treated with alpelisib

PURPOSE: The oral, α-specific phosphatidylinositol-3-kinase (PI3Kα) inhibitor alpelisib is the first PI3K inhibitor approved for the treatment of advanced breast cancer. As alpelisib is a relatively new therapeutic option, specific guidance and a multidisciplinary approach are needed to provide opti...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Lacouture, Mario E., Goncalves, Marcus D., Masharani, Umesh, Aapro, Matti S., O'Shaughnessy, Joyce A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749445/
https://www.ncbi.nlm.nih.gov/pubmed/35016012
http://dx.doi.org/10.1016/j.breast.2021.12.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749445/
https://www.ncbi.nlm.nih.gov/pubmed/35016012
http://dx.doi.org/10.1016/j.breast.2021.12.016

Ejemplares similares